ZOETIS INC

NYSE: ZTS (Zoetis Inc.)

Kemas kini terakhir: semalam, 2:41PM

83.58

0.62 (0.74%)

Penutupan Terdahulu 82.96
Jumlah Dagangan 1,902,530
Harga / Pendapatan (P/E Ke hadapan) 13.83
Harga / Jualan (P/S) 3.67
Harga / Buku (P/B) 10.19
Julat 52 Minggu
68.77 (-17%) — 132.49 (58%)
Hasil Dividen (DY TTM) 2.81%
Margin Keuntungan 27.12%
Margin Operasi (TTM) 38.11%
EPS Cair (TTM) 5.56
Pertumbuhan Hasil Suku Tahunan (YOY) 1.40%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 5.30%
Jumlah Hutang/Ekuiti (D/E MRQ) 145.63%
Nisbah Semasa (MRQ) 1.74
Aliran Tunai Operasi (OCF TTM) 2.94 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 2.30 B
Pulangan Atas Aset (ROA TTM) 15.11%
Pulangan Atas Ekuiti (ROE TTM) 52.09%

AISkor Stockmoo

0.6
Nilai 38% -0.6
AI Insight info NA
Penilaian Relatif info -2.1
Kesihatan Kewangan info 1.7
Masa 38% 2.2
AI Technical info NA
Osilator Teknikal info 2.0
Purata Bergerak Teknikal info 2.5
Sentimen 25% 0.3
Konsensus Penganalisis info 0.0
Sentimen Berita info 1.1
Wang Pintar NA
Aktiviti Orang Dalam info NA
Aliran Institusi info NA
Persekitaran ×0.85
Persekitaran Makro info -3.3
Sektor berbanding Pasaran (6B) -4.0%
Persetujuan Tonggak ×1.06
Tidak dikira dalam skor
Volatiliti Harga info -0.4
Skor Akhir 0.62

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - Specialty & Generic (US) Bercampur Bercampur
Drug Manufacturers - Specialty & Generic (Global) Bercampur Bercampur
Stok Zoetis Inc. Bercampur Menurun

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
ZTS - 2.81% - 10.19
RDY - 0.68% - 3.07
TAK - 4.61% - 1.43
HLN - 2.14% - 1.84
TEVA - - - 6.23
HIMS - - - 18.72

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Sektor Healthcare
Industri Drug Manufacturers - Specialty & Generic
Gaya Pelaburan Mid Value
% Dimiliki oleh Orang Dalam 0.23%
% Dimiliki oleh Institusi 96.61%

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
12 Nov 2026 Yahoo Finance Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief
ZTS' Cytopoint Plus secures a USDA license, offering dogs with allergic dermatitis 75 days of itch relief and a longer interval between injections.
11 Nov 2026 Yahoo Finance Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic Dermatitis
PARSIPPANY, N.J., November 11, 2026--Cytopoint Plus is the first and only USDA-licensed next-generation mAb that provides 75 days of allergic itch relief in a single injection.
11 Nov 2026 Yahoo Finance What Are Wall Street Analysts' Target Price for Zoetis Stock?
Despite significantly underperforming the broader market over the past year, Zoetis continues to receive a cautiously optimistic outlook from Wall Street analysts.
10 Nov 2026 Yahoo Finance Should You Buy Zoetis Stock At This Price?
For questions about this article or underlying research, email [email protected].
10 Nov 2026 Yahoo Finance Zoetis to Participate in the Jefferies Global Healthcare Conference in London
PARSIPPANY, N.J., November 10, 2026--Zoetis Inc. (NYSE:ZTS) today announced that Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 at 2 p.m. GMT.
10 Nov 2026 Yahoo Finance ZTS Q3 2026 deep dive: competitive pressures and margin headwinds weigh on outlook
Animal health company Zoetis (NYSE:ZTS) beat Wall Street’s revenue expectations in Q3 2026, but sales fell by 1.3% year on year to $2.39 billion. The company expects the full year’s revenue to be around $9.27 billion, close to analysts’ estimates. Its non-GAAP profit of $1.75 per share was 15.8%…
09 Nov 2026 Yahoo Finance ZTS Q3 Earnings Call Highlights Competitive Pressures and Outlook
Zoetis beats Q3 earnings estimates despite revenue weakness, as competitive pressures, targeted promotions and product innovation shape its cautious 2027 outlook.
08 Nov 2026 Yahoo Finance What Zoetis (ZTS) Said on Its Q3 Earnings Call
Zoetis (NYSE:ZTS) reported lower third-quarter revenue as competition and weaker veterinary visits pressured its companion animal business, while livestock and diagnostics provided growth. The animal health company narrowed its full-year revenue outlook to the high end of its previous range and rais…
06 Nov 2026 Yahoo Finance Zoetis (ZTS) Stock Price Drops After Q3 Earnings Margin Pressure
Zoetis came into this Q3 2026 earnings release with the stock up over the past month, then the mood flipped. The share price dropped about 3% on the first full trading day after results, a sharp move for a mature animal health business that investors often treat as a steady franchise. The headline…
05 Nov 2026 Yahoo Finance Zoetis: 3 Key Takeaways for Long-Term Investors
Fast lifecycle approvals, such as Simparica Duo, are how Zoetis plans to extend its core franchises beyond today's pressured pet care market.
05 Nov 2026 Yahoo Finance Zoetis (ZTS) Q3 2026 Earnings Call Transcript
Competitive pressure eased in dermatology, but clinic visits softened…
05 Nov 2026 Yahoo Finance No Greyhounds Here: Pet-Health Giant Zoetis Reverses 30% Monthlong Sprint
Zoetis stock reversed lower at the open Thursday after the pet health giant reported "generally fine" third-quarter metrics, an analyst said.
05 Nov 2026 Yahoo Finance ZTS Q3 Earnings Top Estimates, 2026 Profit Outlook Improves, Stock Up
Zoetis beats third-quarter earnings and revenue estimates. Livestock sales growth partially offsets weakness in companion animal products.
05 Nov 2026 Yahoo Finance Zoetis (ZTS) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Zoetis (ZTS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
05 Nov 2026 Yahoo Finance Zoetis (ZTS) Q3 Earnings and Revenues Top Estimates
Zoetis (ZTS) delivered earnings and revenue surprises of +15.89% and +3.89%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Papar semua
Hasil Dividen (DY TTM) 2.81%
Purata Hasil Dividen 5T 0.78%
Nisbah Pembayaran 32.24%
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
21 Apr 2025 06 Feb 2025 03 Jun 2025 0.5 Tunai
21 Jan 2025 12 Dec 2024 04 Mar 2025 0.5 Tunai
31 Oct 2024 10 Oct 2024 03 Dec 2024 0.432 Tunai
18 Jul 2024 22 May 2024 04 Sep 2024 0.432 Tunai
18 Apr 2024 06 Feb 2024 04 Jun 2024 0.432 Tunai
18 Jan 2024 07 Dec 2023 01 Mar 2024 0.432 Tunai
31 Oct 2023 12 Oct 2023 01 Dec 2023 0.375 Tunai
20 Jul 2023 11 May 2023 01 Sep 2023 0.375 Tunai
20 Apr 2023 08 Feb 2023 01 Jun 2023 0.375 Tunai
19 Jan 2023 08 Dec 2022 01 Mar 2023 0.375 Tunai
31 Oct 2022 13 Oct 2022 01 Dec 2022 0.325 Tunai
20 Jul 2022 19 May 2022 01 Sep 2022 0.325 Tunai
20 Apr 2022 08 Feb 2022 01 Jun 2022 0.325 Tunai
19 Jan 2022 07 Dec 2021 01 Mar 2022 0.325 Tunai
28 Oct 2021 14 Oct 2021 01 Dec 2021 0.25 Tunai
20 Jul 2021 20 May 2021 01 Sep 2021 0.25 Tunai
20 Apr 2021 10 Feb 2021 01 Jun 2021 0.25 Tunai
19 Jan 2021 09 Dec 2020 01 Mar 2021 0.25 Tunai
20 Oct 2020 07 Oct 2020 01 Dec 2020 0.2 Tunai
16 Jul 2020 20 May 2020 01 Sep 2020 0.2 Tunai
16 Apr 2020 11 Feb 2020 01 Jun 2020 0.2 Tunai
16 Jan 2020 12 Dec 2019 03 Mar 2020 0.2 Tunai
21 Oct 2019 04 Oct 2019 02 Dec 2019 0.164 Tunai
18 Jul 2019 16 May 2019 03 Sep 2019 0.164 Tunai
17 Apr 2019 13 Feb 2019 03 Jun 2019 0.164 Tunai
17 Jan 2019 13 Dec 2018 01 Mar 2019 0.164 Tunai
19 Nov 2018 11 Oct 2018 03 Dec 2018 0.126 Tunai
19 Jul 2018 16 May 2018 04 Sep 2018 0.126 Tunai
19 Apr 2018 13 Feb 2018 01 Jun 2018 0.126 Tunai
18 Jan 2018 11 Dec 2017 01 Mar 2018 0.126 Tunai
08 Nov 2017 05 Oct 2017 01 Dec 2017 0.105 Tunai
13 Jun 2017 11 May 2017 01 Sep 2017 0.105 Tunai
04 Apr 2017 14 Feb 2017 01 Jun 2017 0.105 Tunai
18 Jan 2017 06 Dec 2016 01 Mar 2017 0.105 Tunai
01 Nov 2016 06 Oct 2016 01 Dec 2016 0.095 Tunai
28 Jun 2016 12 May 2016 30 Aug 2016 0.095 Tunai
05 Apr 2016 19 Feb 2016 01 Jun 2016 0.095 Tunai
19 Jan 2016 16 Dec 2015 01 Mar 2016 0.095 Tunai
03 Nov 2015 01 Oct 2015 01 Dec 2015 0.083 Tunai
11 Aug 2015 21 Jul 2015 01 Sep 2015 0.083 Tunai
07 Apr 2015 27 Feb 2015 02 Jun 2015 0.083 Tunai
20 Jan 2015 17 Dec 2014 03 Mar 2015 0.083 Tunai
03 Nov 2014 02 Oct 2014 02 Dec 2014 0.072 Tunai
18 Aug 2014 31 Jul 2014 02 Sep 2014 0.072 Tunai
23 Apr 2014 26 Mar 2014 02 Jun 2014 0.072 Tunai
28 Jan 2014 19 Dec 2013 04 Mar 2014 0.072 Tunai
30 Oct 2013 12 Sep 2013 02 Dec 2013 0.065 Tunai
30 Jul 2013 20 Jun 2013 02 Sep 2013 0.065 Tunai
29 Apr 2013 28 Mar 2013 06 Jun 2013 0.065 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 1.00 2 0.80
2024 1.73 4 1.06
2023 1.50 4 0.76
2022 1.30 4 0.89
2021 1.00 4 0.41
2020 0.800 4 0.48
2019 0.656 4 0.50
2018 0.504 4 0.59
2017 0.420 4 0.58
2016 0.380 4 0.71
2015 0.332 4 0.69
2014 0.288 4 0.67
2013 0.195 3 0.60
Papar semua

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda